Page last updated: 2024-10-31

modafinil and Allergic Encephalomyelitis

modafinil has been researched along with Allergic Encephalomyelitis in 1 studies

Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.

Research Excerpts

ExcerptRelevanceReference
"Modafinil treatment, given after the onset of symptoms, resulted in an improvement of EAE symptoms and motor impairment, which was correlated with reduced cellular infiltrate and a decreased percentage of T helper (Th) 1 cells in the CNS."1.51Therapeutic treatment with Modafinil decreases the severity of experimental autoimmune encephalomyelitis in mice. ( Andersen, ML; Brandão, WN; Palermo-Neto, J; Peron, JP; Zager, A, 2019)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brandão, WN1
Andersen, ML1
Palermo-Neto, J1
Peron, JP1
Zager, A1

Other Studies

1 other study available for modafinil and Allergic Encephalomyelitis

ArticleYear
Therapeutic treatment with Modafinil decreases the severity of experimental autoimmune encephalomyelitis in mice.
    International immunopharmacology, 2019, Volume: 75

    Topics: Animals; Brain; Central Nervous System Stimulants; Cytokines; Encephalomyelitis, Autoimmune, Experim

2019